Next Article in Journal
Prevalence and Phylogenetic Analysis of Parvovirus (B19V) among Blood Donors with Different Nationalities Residing in Qatar
Next Article in Special Issue
In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2
Previous Article in Journal
NSP16 2′-O-MTase in Coronavirus Pathogenesis: Possible Prevention and Treatments Strategies
Previous Article in Special Issue
Treatment Protocol for COVID-19 Based on T2R Phenotype
Brief Report

Amantadine Inhibits SARS-CoV-2 In Vitro

1
Merz Pharmaceuticals GmbH, 60318 Frankfurt, Germany
2
Robert-Koch-Institut, Zentrum für Biologische Gefahren und Spezielle Pathogene: Hochpathogene Viren (ZBS 1), 13353 Berlin, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Kenneth Lundstrom
Received: 15 February 2021 / Revised: 17 March 2021 / Accepted: 19 March 2021 / Published: 24 March 2021
(This article belongs to the Special Issue Vaccines and Therapeutics against Coronaviruses)
Since the SARS-CoV-2 pandemic started in late 2019, the search for protective vaccines and for drug treatments has become mandatory to fight the global health emergency. Travel restrictions, social distancing, and face masks are suitable counter measures, but may not bring the pandemic under control because people will inadvertently or at a certain degree of restriction severity or duration become incompliant with the regulations. Even if vaccines are approved, the need for antiviral agents against SARS-CoV-2 will persist. However, unequivocal evidence for efficacy against SARS-CoV-2 has not been demonstrated for any of the repurposed antiviral drugs so far. Amantadine was approved as an antiviral drug against influenza A, and antiviral activity against SARS-CoV-2 has been reasoned by analogy but without data. We tested the efficacy of amantadine in vitro in Vero E6 cells infected with SARS-CoV-2. Indeed, amantadine inhibited SARS-CoV-2 replication in two separate experiments with IC50 concentrations between 83 and 119 µM. Although these IC50 concentrations are above therapeutic amantadine levels after systemic administration, topical administration by inhalation or intranasal instillation may result in sufficient amantadine concentration in the airway epithelium without high systemic exposure. However, further studies in other models are needed to prove this hypothesis. View Full-Text
Keywords: amantadine; antiviral drugs; Covid-19; SARS-CoV-2 amantadine; antiviral drugs; Covid-19; SARS-CoV-2
Show Figures

Figure 1

MDPI and ACS Style

Fink, K.; Nitsche, A.; Neumann, M.; Grossegesse, M.; Eisele, K.-H.; Danysz, W. Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses 2021, 13, 539. https://0-doi-org.brum.beds.ac.uk/10.3390/v13040539

AMA Style

Fink K, Nitsche A, Neumann M, Grossegesse M, Eisele K-H, Danysz W. Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses. 2021; 13(4):539. https://0-doi-org.brum.beds.ac.uk/10.3390/v13040539

Chicago/Turabian Style

Fink, Klaus; Nitsche, Andreas; Neumann, Markus; Grossegesse, Marica; Eisele, Karl-Heinz; Danysz, Wojciech. 2021. "Amantadine Inhibits SARS-CoV-2 In Vitro" Viruses 13, no. 4: 539. https://0-doi-org.brum.beds.ac.uk/10.3390/v13040539

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop